RATIONALE. Myelodysplastic syndromes (MDS) are rare cancers with unmet medical needs. Study of MDS has been rapidly transformed by genome characterization. HYPOTHESIS. We hypothesize that comprehensive analyses of large patient population will allow to correctly estimate the effect of each mutation on clinical outcomes, and that environmental factors, including immune dysfunctions may influence the development of MDS, its clonal evolution and response to treatmentsAIMS: 1) Investigate gene mutations and environmental factors influencing the development of MDS, and develop biomarkers for early identification of individuals at risk; 2) Develop personalized prognostic/predictive models for MDS patients through integration of comprehensive genomic/clinical information; 3) Define biomarkers to better stratify the individual probability of response to specific treatmentsMETHODS. EuroBloodNet, the European Reference Network in rare hematological diseases, will provide a basis for research activitiesAIM1: to study genomic features of clonal dominance in elderly subjects enrolled in 3 large population-based studies and to describe the dynamics of clonal establishment and evolution; to study bone marrow microenvironment to identify non-mutation factors influencing MDS development AIM2: to develop inclusive statistical models to accurately predict clinical outcome at individual level, based on large MDS populations with comprehensive genomic and clinical data AIM3: to analyze data of mutational screening and immune profiles from patients enrolled in prospective trials, to provide evidence on genetic/immunologic profiles associated with probability of response to specific compounds.
SMD
síndrome mielodisplásico
neoplasia mieloide
cáncer hematológico raro
Acción Estratégica en Salud (AES)
01/01/2019 - 31/12/2021
SOLE RISTOL, FRANCESC
FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS
FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS
Cataluña
Barcelona
148,830 €